Invirsa, a Columbus-based pharmaceutical company, today announced execution of a license agreement with the Abigail Wexner Research Institute (AWRI) at Nationwide Children's Hospital as Invirsa seeks to broaden its treatment platform to address respiratory diseases.
The announcement coincides with Invirsa's securing a $16.9 million contract from the government agency involved in the development of medical countermeasures.
The contract from the Biomedical Advanced Research and Development Authority (BARDA), part of the Office of the Assistant Secretary for Preparedness and Response at the U.S. Department of Health and Human Services, will help move Invirsa's investigational product INV-102 to clinical trials and request FDA approval. The contract includes options for an additional $12.6 million upon completion of scientific milestones.
INV-102 is a compound intended to target conditions associated with DNA damage, including ocular, lung and skin injuries.
DNA damage is a fundamental part of many types of injury, (particularly those from infectious diseases caused by viruses or bacteria), from radiation injury (ultraviolet and X-ray), or from chemical exposure such as sulfur mustard. INV-102 supports the cell's ability to repair its DNA, which in turn optimizes the wound healing process. The product is an innovative approach to treat injury and disease.
Our license agreement with AWRI will greatly enhance our work, as the research institute is recognized as a national leader in pediatric health care research. Lung damage is something that occurs across disease states, across age ranges. We know that respiratory diseases affect children disproportionately, and as we expand our INV-102 treatment platform into other conditions such as viral pneumonia, having AWRI as our license partner reinforces the efficacy of our work."
Robert Shalwitz, Chief Executive Officer of Invirsa, CincyTech
Social media reshapes children’s diets and body image with alarming consequences